185 related articles for article (PubMed ID: 36010573)
1. In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment.
Wang F; Han Y; Sang W; Wang L; Liang X; Wang L; Xing Q; Guo Y; Zhang J; Zhang L; Zukela T; Xiaokereti J; Lu Y; Zhou X; Tang B; Li Y
Cells; 2022 Aug; 11(16):. PubMed ID: 36010573
[TBL] [Abstract][Full Text] [Related]
2. KCNQ1 G219E and TRPM4 T160M polymorphisms are involved in the pathogenesis of long QT syndrome: A case report.
Zhao Y; Feng M; Shang LX; Sun HX; Zhou XH; Lu YM; Zhang L; Xing Q; Li YD; Tang BP
Medicine (Baltimore); 2021 Jan; 100(2):e24032. PubMed ID: 33466149
[TBL] [Abstract][Full Text] [Related]
3. Modelling the long QT syndrome with induced pluripotent stem cells.
Itzhaki I; Maizels L; Huber I; Zwi-Dantsis L; Caspi O; Winterstern A; Feldman O; Gepstein A; Arbel G; Hammerman H; Boulos M; Gepstein L
Nature; 2011 Mar; 471(7337):225-9. PubMed ID: 21240260
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic mechanism and gene correction for LQTS-causing double mutations in KCNQ1 using a pluripotent stem cell model.
Wang Z; Wang L; Liu W; Hu D; Gao Y; Ge Q; Liu X; Li L; Wang Y; Wang S; Li C
Stem Cell Res; 2019 Jul; 38():101483. PubMed ID: 31226583
[TBL] [Abstract][Full Text] [Related]
5. Studying KCNQ1 Mutation and Drug Response in Type 1 Long QT Syndrome Using Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Wei H; Wu J; Liu Z
Methods Mol Biol; 2018; 1684():7-28. PubMed ID: 29058180
[TBL] [Abstract][Full Text] [Related]
6. Proof of concept for monoclonal antibody therapy in a cellular model of acquired long QT syndrome type 3.
Kis L; Li J
Am J Physiol Heart Circ Physiol; 2024 Jan; 326(1):H89-H95. PubMed ID: 37947435
[TBL] [Abstract][Full Text] [Related]
7. Complex aberrant splicing in the induced pluripotent stem cell-derived cardiomyocytes from a patient with long QT syndrome carrying KCNQ1-A344Aspl mutation.
Wuriyanghai Y; Makiyama T; Sasaki K; Kamakura T; Yamamoto Y; Hayano M; Harita T; Nishiuchi S; Chen J; Kohjitani H; Hirose S; Yokoi F; Gao J; Chonabayashi K; Watanabe K; Ohno S; Yoshida Y; Kimura T; Horie M
Heart Rhythm; 2018 Oct; 15(10):1566-1574. PubMed ID: 29857160
[TBL] [Abstract][Full Text] [Related]
8. Generation of induced pluripotent stem cell lines from patients with LQT1 caused by heterozygous mutations in the KCNQ1 gene.
Ren L; Jahng JWS; Belbachir N; Cook Z; Rivero GC; Perez MV; Wu JC
Stem Cell Res; 2024 Aug; 78():103443. PubMed ID: 38763038
[TBL] [Abstract][Full Text] [Related]
9. MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes.
Lee YK; Sala L; Mura M; Rocchetti M; Pedrazzini M; Ran X; Mak TSH; Crotti L; Sham PC; Torre E; Zaza A; Schwartz PJ; Tse HF; Gnecchi M
Cardiovasc Res; 2021 Feb; 117(3):767-779. PubMed ID: 32173736
[TBL] [Abstract][Full Text] [Related]
10. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
Matsa E; Rajamohan D; Dick E; Young L; Mellor I; Staniforth A; Denning C
Eur Heart J; 2011 Apr; 32(8):952-62. PubMed ID: 21367833
[TBL] [Abstract][Full Text] [Related]
11. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.
Lahti AL; Kujala VJ; Chapman H; Koivisto AP; Pekkanen-Mattila M; Kerkelä E; Hyttinen J; Kontula K; Swan H; Conklin BR; Yamanaka S; Silvennoinen O; Aalto-Setälä K
Dis Model Mech; 2012 Mar; 5(2):220-30. PubMed ID: 22052944
[TBL] [Abstract][Full Text] [Related]
12. Disease characterization using LQTS-specific induced pluripotent stem cells.
Egashira T; Yuasa S; Suzuki T; Aizawa Y; Yamakawa H; Matsuhashi T; Ohno Y; Tohyama S; Okata S; Seki T; Kuroda Y; Yae K; Hashimoto H; Tanaka T; Hattori F; Sato T; Miyoshi S; Takatsuki S; Murata M; Kurokawa J; Furukawa T; Makita N; Aiba T; Shimizu W; Horie M; Kamiya K; Kodama I; Ogawa S; Fukuda K
Cardiovasc Res; 2012 Sep; 95(4):419-29. PubMed ID: 22739119
[TBL] [Abstract][Full Text] [Related]
13. Generation of eight human induced pluripotent stem cell (iPSC) lines from familial Long QT Syndrome type 1 (LQT1) patients carrying KCNQ1 c.1697C>A mutation (NUIGi005-A, NUIGi005-B, NUIGi005-C, NUIGi006-A, NUIGi006-B, NUIGi006-C, NUIGi007-A, and NUIGi007-B).
Ge N; Liu M; Krawczyk J; McInerney V; Galvin J; Shen S; O'Brien T; Prendiville T
Stem Cell Res; 2019 Aug; 39():101502. PubMed ID: 31415974
[TBL] [Abstract][Full Text] [Related]
14. Patient-specific induced pluripotent stem-cell models for long-QT syndrome.
Moretti A; Bellin M; Welling A; Jung CB; Lam JT; Bott-Flügel L; Dorn T; Goedel A; Höhnke C; Hofmann F; Seyfarth M; Sinnecker D; Schömig A; Laugwitz KL
N Engl J Med; 2010 Oct; 363(15):1397-409. PubMed ID: 20660394
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Ma D; Wei H; Lu J; Huang D; Liu Z; Loh LJ; Islam O; Liew R; Shim W; Cook SA
Stem Cell Res Ther; 2015 Mar; 6(1):39. PubMed ID: 25889101
[TBL] [Abstract][Full Text] [Related]
16. Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome.
Jouni M; Si-Tayeb K; Es-Salah-Lamoureux Z; Latypova X; Champon B; Caillaud A; Rungoat A; Charpentier F; Loussouarn G; Baró I; Zibara K; Lemarchand P; Gaborit N
J Am Heart Assoc; 2015 Sep; 4(9):e002159. PubMed ID: 26330336
[TBL] [Abstract][Full Text] [Related]
17. A computational model of induced pluripotent stem-cell derived cardiomyocytes for high throughput risk stratification of KCNQ1 genetic variants.
Kernik DC; Yang PC; Kurokawa J; Wu JC; Clancy CE
PLoS Comput Biol; 2020 Aug; 16(8):e1008109. PubMed ID: 32797034
[TBL] [Abstract][Full Text] [Related]
18. TRPM4 non-selective cation channel variants in long QT syndrome.
Hof T; Liu H; Sallé L; Schott JJ; Ducreux C; Millat G; Chevalier P; Probst V; Guinamard R; Bouvagnet P
BMC Med Genet; 2017 Mar; 18(1):31. PubMed ID: 28315637
[TBL] [Abstract][Full Text] [Related]
19. Modeling long QT syndromes using induced pluripotent stem cells: current progress and future challenges.
Friedrichs S; Malan D; Sasse P
Trends Cardiovasc Med; 2013 May; 23(4):91-8. PubMed ID: 23266156
[TBL] [Abstract][Full Text] [Related]
20. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
Terrenoire C; Wang K; Tung KW; Chung WK; Pass RH; Lu JT; Jean JC; Omari A; Sampson KJ; Kotton DN; Keller G; Kass RS
J Gen Physiol; 2013 Jan; 141(1):61-72. PubMed ID: 23277474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
